Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Humbert, P. Lowe, C. Ferioli, C. Martin, M. Blogg (Clamart, France; Basel, Switzerland; Horsham, United Kingdom). Returning asthma symptoms correlate with free IgE upon omalizumab cessation. Eur Respir J 2007; 30: Suppl. 51, 3639

Member's Comments

No comment yet.

Related content which might interest you: Free serum IgE suppression with omalizumab and clinical outcomes in asthma Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Chlamydia pneumoniae(Cp)-specific IgE is associated with asthma severity Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Is omalizumab response influenced by passive smoking in severe asthma? Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Long-term asthma control with omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Source: Eur Respir J 2005; 26: Suppl. 49, 47s Year: 2005 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002 Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma Source: International Congress 2018 – Tests and trends in asthma Year: 2018 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Improved symptom relief with omalizumab in the treatment of allergic rhinitis Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Evaluation of inhalant allergen-specific IgE in wheezing infants as predictor for persistent symptoms Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005